环硅酸锆钠上市后安全性：基于FDA报告系统的药物警戒研究数据集

资源简介

环硅酸锆钠上市后安全性：基于FDA报告系统的药物警戒研究数据集

【数据集背景】

本数据集源站标题为《Post-marketing safety associated with sodium zirconium cyclosilicate: a pharmacovigilance study based on the FDA reporting system》。配套论文《Post-marketing safety associated with sodium zirconium cyclosilicate: a pharmacovigilance study based on the FDA reporting system》发表于 Expert Opinion on Drug Safety（2025），DOI：10.1080/14740338.2025.2486310。项目资助方：This manuscript was funded by the Project of Yongchuan Hospital of Chongqing Medical University [YJLC202121].。源站首次发布：2025-03-28。

【数据内容】

源站原始描述：Sodium zirconium cyclosilicate (SZC) is a novel oral therapy for hyperkalemia with limited adverse reactions documented on its label. Accordingly, the objective of this study was to investigate real-world adverse events (AEs) associated with SZC using the FDA Adverse Event Reporting System (FAERS). Relevant data regarding SZC were extracted from FAERS, and signal detection was conducted using four distinct algorithms. The Weibull shape parameter characterized the AE onset time. Kaplan-Meier anal…

【数据结构与技术规格】

文件数 4 个，合计 64.84 KB。ieds_a_2486310_sm4444.docx：application/vnd.openxmlformats-officedocument.wordprocessingml.document，13.77 KB。ieds_a_2486310_sm4443.docx：application/vnd.openxmlformats-officedocument.wordprocessingml.document，18.68 KB。ieds_a_2486310_sm4442.docx：application/vnd.openxmlformats-officedocument.wordprocessingml.document，12.63 KB。数据集 DOI：10.6084/m9.figshare.28682880.v1。

【主题与分类】

源站学科分类：Medicine、Pharmacology、Biotechnology、Biological Sciences not elsewhere classified、Science Policy。主题标签：Adverse event、disproportionality analysis、FAERS、pharmacovigilance、sodium zirconium cyclosilicate。

【适用方向】

源站学科分类标注为 Medicine、Pharmacology、Biotechnology、Biological Sciences not elsewhere classified、Science Policy。

【获取与许可】

源站页面：https://tandf.figshare.com/articles/dataset/Post-marketing_safety_associated_with_sodium_zirconium_cyclosilicate_a_pharmacovigilance_study_based_on_the_FDA_reporting_system/28682880

使用许可：CC BY 4.0（https://creativecommons.org/licenses/by/4.0/）。

规范引用：Post-marketing safety associated with sodium zirconium cyclosilicate: a pharmacovigilance study based on the FDA reporting system. Taylor & Francis. Chen, Jiankang; Lu, Zuzhuang; Luo, Honghong; Wang, Tiaomin; Qin, Xiaoying

【使用注意】

· 源站最后修改于 2026-09-01，引用时请注意版本时效。